Innovent Biologics, a leading biopharmaceutical company, presented multiple clinical and preclinical results at the 2026 American Diabetes Association Scientific Sessions, focusing on its innovative obesity and metabolic pipeline. Key highlights included the clinical efficacy of mazdutide, a dual agonist for type 2 diabetes and obesity, which showed significant weight loss and improved glycemic control in adults and adolescents. The company also shared promising data on IBI3032, an oral GLP-1 receptor agonist that exhibited superior weight-loss efficiency compared to existing treatments during preclinical studies. Additionally, IBI3040, a novel amylin analog, demonstrated potent weight loss effects and potential synergistic benefits when combined with other therapies. Innovent's IBI3042, a once-weekly oral GLP-1 receptor agonist, is set to enter clinical studies by the end of 2026, providing a more convenient treatment option. Lastly, IBI3046, an INHBE-targeting siRNA, has shown durable effects in weight control and fat reduction, indicating its potential to redefine metabolic disease management. These advancements underscore Innovent's commitment to addressing unmet needs in obesity treatment.